Translations:Anti-obesity medication/22/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
Tags: Mobile edit Mobile web edit
 
(No difference)

Latest revision as of 18:16, 7 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Anti-obesity medication)
|-
|[[Metformin]]
|Glucophage
|Unknown
|Approved for type 2 diabetes
|5.6 percent
|-
|[[Cagrilintide]]
|
|[[Dual amylin and calcitonin receptor agonist]] (DACRA)
|Not approved
|7.8 percent
|-
|[[Cagrilintide/semaglutide]]
|CagriSema
|DACRA/GLP-1 agonist combination
|Not approved
|15.4 percent after 32 weeks
|}

|- |Metformin |Glucophage |Unknown |Approved for type 2 diabetes |5.6 percent |- |Cagrilintide | |Dual amylin and calcitonin receptor agonist (DACRA) |Not approved |7.8 percent |- |Cagrilintide/semaglutide |CagriSema |DACRA/GLP-1 agonist combination |Not approved |15.4 percent after 32 weeks |}

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Anti-obesity_medication/22/en&oldid=125278"